Navigation Links
NW Bio Reaches Agreement With Convertible Note Holders
Date:3/10/2017

BETHESDA, Md., March 10, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors ("Whitebox"), holder of $11 million of NW Bio convertible senior notes.

With these Notes otherwise due today, as previously disclosed, NW Bio and Whitebox have negotiated a time payment approach tailored to the Company's development schedule with increasing periodic payments over the course of the next 4 months.  As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock.

The details of this cooperative arrangement are available in the 8-K filed by the Company this morning, which can be found on NW Bio's website at www.nwbio.com  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers.  It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion.  The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer 

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to fulfill its repayment obligations under the repurchase agreement, the risk of a default in its obligations under any installment under the agreement, the Company's ongoing ability to raise additional capital including to satisfy its obligations under the repurchase agreement, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nw-bio-reaches-agreement-with-convertible-note-holders-300421869.html


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Indivumeds Cancer Database Reaches a Global Scale Through Partnership With the National Cancer Tissue Biobank (NCTB), Indian Institute of Technology Madras, Chennai, India
2. Purcell Julie & Lefkowitz LLP Is Investigating HedgePath Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
3. Kalorama: Medical Computed Tomography Systems Market Reaches $4.9 Billion
4. Cardinal Health Reaches Settlement With West Virginia
5. ResMed Reaches Historic One Billionth Night of Sleep Monitored
6. Kalorama: Infusion Pump Market Reaches $7 Billion
7. Kalorama: Global Medical Device Market Reaches $381 Billion
8. LIGHT FOR THE WORLD Reaches Milestone in Fight Against Trachoma in 2015: Almost Six Million People Prevented From Going Blind
9. FamilyWize Reaches $1 Billion Saved Milestone
10. Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
11. Kalorama: Led by Self-Testing, Global POC Pregnancy and Fertility Testing Market Reaches $851 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... 2017 , ... Parker at Stonegate, an assisted living residence ... caregivers, volunteers, thought leaders, researchers, educators and partners leading the way in services ... refresh the carpeting with the goal of maintaining the same precise colors and ...
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... Ca (PRWEB) , ... August 18, 2017 , ... ... quality liquid handling handheld devices. Through an educational webinar, they will present the ... users a chance to learn how easy you can automate everyday pipetting tasks. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... assistance that serves communities throughout southern Florida, is working to support the Take ... to children from low income families. , The Take Stock In Children Foundation ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become ... and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
Breaking Medicine News(10 mins):